Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Dose Escalation Study to Evaluate Safety, Tolerability, Biodistribution and Efficacy of [90Y]Y-PentixaTher for the Therapy of Recurrent or Refractory Primary or Isolated Secondary Central Nervous System Lymphoma.

NCT06132737 is registered in ClinicalTrials.gov with Pentixapharm AG as lead sponsor.

NCT NCT06132737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Dose Escalation Study to Evaluate Safety, Tolerability, Biodistribution and Efficacy of [90Y]Y-PentixaTher for the Therapy of Recurrent or Refractory Primary or Isolated Secondary Central Nervous System Lymphoma.
Lead sponsor
Pentixapharm AG
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 7, 2023
Completion date
March 26, 2028
Enrollment
15 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cns lymphoma